健康元

News
Group real-time dynamics and cutting-edge information in the field of One Health
img
Your location:
Homepage
/
Subordinate Company
In the evening of 24th, Aug., Joincare Pharmaceutical Group Industry Co., Ltd (Joincare) has released the public notification that the company gained the ‘Drug Production License’ (DPL). Until now, the two major combination medicinal products developed by Joincare, Compound Ipratropium Bromide Solution for Inhalation and Levosalbutamol Hydrochloride Nebuliser Solution, have begun to be manufactured.
Shanghai Securities News and cnstock news Joincare announced on the evening of April 9 that the Compound Ipratropium Bromide Solution for Inhalation developed by it has recently received the Drug Re
The NCV outbreaking recently is a serious public health emergency. Its fastest, broadest contagion has brought about the more difficulty in its prevention than ever since the foundation of China.
TraditionalChineseMedicineplaysabigroleinthepandemicbattle AsthesituationofbattlingwithCOVID-19inChinahasgraduallygottenbetter,Chinaturnstooffersupporttoothercountriesinneedafterreceivingfriendlyassis
According to Traditional Chinese Medicine Therapeutic Schedule for Novel Coronavirus Pneumonia (2nd Trial Edition) released on 2nd, Feb., doctors are recommended to apply ginseng antiphlogistic powder (GAP) into therapy if the patients show wind-cold on appearance, lack of Qi and stagnation of dampness-evil.
Summary: On January 28, in order to fight against the pneumonia outbreak caused by the novel coronavirus, Joincare Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Joincare Group"), and
In the mid-winter season, Jiankangyuan & Livzon Group’s chronic disease poverty alleviation once again received good news. On December 12, the company entered the northeast region for the first time and signed a chronic disease poverty alleviation agreement with Xianghai National Nature Reserve to provide villagers around the reserve. Send warmth.     In the morning of the same day, Yang Shaoan, Party Secretary of Xianghai Township, Tongyu County, Jilin Province, Wang Wenhe, Township Mayor, Yang Jun, Deputy Secretary of Xianghai National Nature Reserve, Hua Shuchun, Director of Xianghai Township Health Center, and Wang Chunli, Director of Xianghai Ecological Protection Center, etc. The leaders met with the volunteers of Jiankangyuan Poverty Alleviation, and the two parties had in-depth exchanges on the content of chronic disease poverty alleviation and the way of drug distribution. Secretary Yang said that Joincare & Livzon Group has contributed to poverty alleviation to the sea and expressed gratitude and praise for its charity based on public welfare and repaying society. Subsequently, Joincare & Livzon Group and Xianghai National Nature Reserve formally signed a chronic disease poverty alleviation agreement. Xianghai is a national AAAA-level nature reserve. There are 293 species of birds in the area. It has been reviewed by the World Wildlife Fund as an "A-level nature reserve of international significance" and is listed in the "List of Internationally Important Wetlands". And the Biosphere Committee approved to join the "Chinese Man and Biosphere Conservation Network", a national forest and wildlife nature reserve. At the same time, Xianghai is also the protection base of the Taohuayuan Foundation, with an entrusted management area of ​​175 square kilometers. Joincare & Livzon Group’s Chronic Disease Poverty Alleviation entered Xianghai this time and will donate 1 million medicines to chronic disease villagers in 16 villages, mainly for hypertension, hyperlipidemia, cardiovascular and gastric diseases, and help medical poverty alleviation. Since the start of the chronic disease poverty alleviation project at the end of 2018, Joincare & Livzon Group has carried out chronic disease poverty alleviation in eight counties in Sichuan, Shanxi, Gansu and Jilin provinces. Whether poor or rich, every elderly person has the right to enjoy a healthy old age. Joincare & Livzon Group is a faithful practitioner of this poverty alleviation purpose.
Recently, the State Intellectual Property Office issued the "2019 National Intellectual Property Advantage Demonstration Enterprise Review and Re-inspection Results Announcement". Joincare Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Healthcare Pharmaceutical Group") relies on its excellent independent innovation capabilities and A good intellectual property construction management system has passed the rigorous review by the expert group, and successfully won the highest honor awarded by the state for the creation, use, protection, and management of corporate intellectual property rights-the "2019 National Intellectual Property Demonstration Enterprise". It is reported that among the 274 national intellectual property demonstration enterprises in the country this time, only 4 are recommended by Shenzhen Intellectual Property Office, namely, Joincare Pharmaceutical Group, DJI Innovation, Hanyu Pharmaceutical and China Construction Steel. All are industry leaders. It is worth mentioning that, Shenzhen Haibin Pharmaceutical Co., Ltd., a subsidiary of Joincare Pharmaceutical Group, was also awarded the "National Intellectual Property Advantage Enterprise". The two important awards in one fell swoop are that Joincare Pharmaceutical Group always attaches importance to independent research and development of technology, Another fruit of the in-depth implementation of the intellectual property strategy. (The picture comes from the official website of the State Intellectual Property Office) It is reported that in order to implement the spirit of the "National Intellectual Property Strategy Outline" and the "National Patent Business Development Strategy (2011-2020)", to accelerate the formation of a group of backbone enterprises with independent intellectual property rights and well-known brands and strong international competitiveness. The "Notice on Carrying out the Cultivation of National Intellectual Property Advantage Enterprises and Model Enterprises" (Guo Zhi Fa Guan Zi [2013] No. 36) requires that the State Intellectual Property Office assesses national intellectual property model enterprises from 2013. The award of this honor is not only the highest honor awarded by the state to the creation, application, protection, management and other aspects of enterprise intellectual property rights, but also the highest evaluation given by the state to enterprise intellectual property management work. The enterprises that have passed the review are regarded as the leaders of regional intellectual property development Sheep will provide strong support for the development of intellectual property rights. (The picture comes from the official website of the State Intellectual Property Office) Over the years, Joincare Pharmaceutical Group has persisted in implementing the "Enterprise Intellectual Property Management Regulations", established a solid and complete intellectual property management system, attaches great importance to the research and development and innovation of pharmaceutical technology, and has successively obtained a number of intellectual property rights. At the same time, relying on its strength and experience in the field of general health, the company continues to develop pharmaceutical technology with independent intellectual property rights. It has developed from a well-known health care product company to a large health pharmaceutical group with strong comprehensive strength in China. Its business covers chemical preparations, Numerous sectors including APIs, Chinese medicines, health products, OTC, and diagnostic reagents. Joincare Pharmaceutical Group and Shenzhen Haibin Pharmaceutical Co., Ltd. were awarded the "2019 National Intellectual Property Demonstration Enterprise" and "National Intellectual Property Advantage Enterprise" respectively. They are authoritative institutions for the group's independent research and development capabilities, intellectual property protection capabilities and future markets. The best affirmation of development potential also marks that Joincare Pharmaceutical Group has reached a new level in the management of intellectual property rights. Relevant leaders of the group stated that in the future, the company will continue to increase investment in scientific research, focus on core technology research and development, and improve related intellectual property protection mechanisms, strengthen the transformation of scientific research results, while consolidating and enhancing its core competitive advantages, it will help promote the Guangdong-Hong Kong-Macao University Innovative development in the Bay Area.
1
2

Quick Navigation

Service Hotline

Service

Hotline

Copyright © Joincare Pharmaceutical Group Industry Co., Ltd. All Rights Reserved.  Powered by:www.300.cn Zhuhai  粤ICP备14024104号